Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings

The transcript features an interview with Merck's CFO, Marcus Kunitz, discussing the company's financial performance, particularly the strong results from the Life Sciences division. The CFO addresses the potential for spinning off the division, the strategic focus on maintaining a balanced portfolio, and the impact of M&A activities. The conversation shifts to the healthcare sector, highlighting the decline in Rebif sales and the launch of a new MS drug, Madame Claude. Bavencio's sales performance and future expectations are also discussed. The interview concludes with an analysis of the economic outlook, noting strengths in healthcare and life sciences, but challenges in the automotive market.

What are the future plans regarding M&A opportunities as mentioned by the CFO?

How does the CFO perceive the current state of the German economy in relation to their business?